Ahmed Magdy Rabea, Assistant Professor of Medical Oncology and Hematology at National Cancer Institute, posted on LinkedIn:
“Had the pleasure of joining my friend Amr Shafik in a dynamic and insightful debate on the evolution of Anti-EGFR therapies in advanced NSCLC during the CAIRO Journal Club – Lung 360 meeting in the beautiful city of Ismailia, Egypt.
We explored how the field has rapidly evolved, from first-generation EGFR TKIs to the newer targeted agents, and discussed the challenges and opportunities that come with resistance mechanisms, sequencing strategies, and future directions in precision oncology, overcoming resistance with adding other strategies
It is an honor to be one of founding members of CAIRO Journal Club that foster meaningful dialogues and bring the oncology community together to push the boundaries of knowledge and care.”
Read more posts featuring Ahmed Magdy Rabea.